Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

摘要

Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nabpaclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.